SUMMARY Sera from patients with heart disease were examined by single sandwich indirect immunofluorescence for the presence of antibodies to human heart muscle. Endocardial biopsy specimens were also examined by direct inmunofluorescence for deposition of antibodies in vivo. No consistent or specific abnormality was found in the biopsy specimens or sera of patients with congestive cardiomyopathy. The presence of anti-heart antibodies in cardiac disease appears to reflect damage to cardiac muscle whatever the cause. Immunofluorescence is an insensitive test for anti-heart antibodies.
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It has been suggested that cardiac damage in congestive cardiomyopathy may be mediated by an autoimmine mechanism.I The role of humoral abnormalities, in particular type II hypersensitivity, has received considerable attention,2-4 but the results and their interpretation vary widely. Previous findings in our department (using baboon heart as substrate) suggested that the role of humoral autoimmunity as a primary cause of congestive cardiomyopathy is not proven5; we undertook a further study to confirm or refute the findings.
Our aims were (a) to detect serum autoantibodies to human heart muscle, (b) to detect evidence of in vivo antibody fixation by cardiac antigens, and (c) to demonstrate immune complex deposition in and around myocardial vessels.
Patients and methods

SEROLOGICAL STUDY
Sera of 95 patients were examined for the presence of antiheart antibodies. Forty three had cardiomyopathy according to the classification of Goodwin and Oakley6: 28 had congestive cardiomyopathy diagnosed both clinically and by cardiac catheterisation and endomyocardial biopsy, with one exception in which the diagnosis was confirmed at necropsy and 15 had hypertrophic cardiomyopathy, in all but one of whom the diagnosis was confirmed at catheterisation. Nine of the 15 patients in the latter group had a left ventricular outflow tract obstruction detected at catheterAccepted for publication 22 June 1983 isation. Sixteen patients had ischaemic heart disease and nine rheumatic heart disease; six subjects were healthy controls; and the remaining 21 patients comprised a miscellaneous group including five with post-infarct/post-cardiotomy syndrome ( Table 1) . The groups were classified symptomatically according to the New York Heart Association (NYHA) criteria at the time of venesection (Table 2 ): 50%/o of patients with congestive cardiomyopathy and 44% 0oith ischaemic heart disease were in groups IIb, III, and IV.
Serum was separated from cells immediately after venesection and stored at -20°C. Sections from normal human left ventricle and congestive cardiomyopathic left ventricle were used as the substrate. The normal heart was obtained within 14 hours of death from a woman who died after trauma. The congestive cardiomyopathic heart was obtained within 24 hours of death from a 16 year old boy' in whom the diagnosis of congestive cardiomyopathy had been confirmed by invasive investigation and necropsy. The hearts were stored at -70°C. Sections of 7 ,um were cut on a cryostat at -20°C from portions of these ventricles and dried in air for at least 10 minutes before storage at -70°C until use.
The single sandwich immunofluorescence technique was used, as previous work in this departments has not shown any appreciable advantage of the double sandwich technique. Sera were tested at a dilution of 1/5 in phosphate buffered saline (PBS): 05 ml was incubated with sections of normal and congestive cardiomyopathic heart at room temperature for 30 minutes. The serum was removed by washing with PBS for five minutes. A drop (approximately 0-03 ml) of fluorescein isothiocyanate conjugated anti-human 390 IgG (Atlantic Antibodies) was placed on each section, and after a further 30 minutes the slides were washed in PBS, mounted in buffered glycerol, and viewed under the fluorescence microscope (Leitz Ortholux).
A negative control serum sample from a healthy subject and a known positive serum sample were included in each batch of slides. The sections were viewed blindly and independently by two observers. Fluorescence was graded as positive (+); weak or no fluorescence was regarded as negative (-). Each patient had serum viewed on two sections, one congestive cardiomyopathic heart and one normal heart: thus if both observers graded fluorescence as positive in both sections a maximum total of 4+ could be scored for the patient.
BIOPSY STUDY
Fifty four endomyocardial biopsy specimens were obtained at the time of cardiac catheterisation from 53 subjects. Of these, 22 had congestive cardiomyopathy, 14 hypertrophic cardiomyopathy, and five ischaemic heart disease. The diagnoses in the Table 1 . Thirteen of the first group and six of the second were also included in the serological study for anti-heart antibodies,
The biopsy specimens were obtained at cardiac catheterisation using a King's bioptome7 from the right ventricular septum in three cases and from the left ventricle in the remainder. Each specimen was placed in a screw topped ampoule, flash frozen in liquid nitrogen within 30 minutes of collection, and stored at -70°C. The specimens were mounted in OCT embedding compound (Miles Laboratories) and eight 7 ,im sections were cut on to a slide at -20°C in a cryostat, air dried for at least 10 minutes, and stored at -70°C. When required, the sections were air dried and washed in PBS for 10 minutes. The conjugates were placed on the slides: fluorescein isothiocyanate conjugated anti-human IgG, IgM, and IgA (Atlantic Antibodies), complement (C3) (Kallestad), and fibrin (Hyland) were used. The sections were incubated for 30 minutes in a moist box at room temperature, rinsed, and washed in PBS for 10 minutes. The sections were mounted in 90% glycerol and viewed under the ultraviolet microscope. The sections were viewed blindly and independently by two observers (PJL and RT). The presence and site of increased fluorescence were noted.
All sections were viewed under a Leitz Ortholux II microscope with Epi illumination using a super pressure mercury source (HBO 50), a Balzer filter exciter, a red cut off filter, and a yellow barrier filter.
STATISTICAL METHOD
The significance of the intraobserver variation was measured using the x2 test. Comparisons between the patient groups were made using the x2 test for independent samples.8
Results
SEROLOGICAL STUDY
All 95 patients had sera examined: 16 had the test repeated on at least one occasion using the same stored sera. The observers' findings were in agreement for 73% of the sections viewed. In those cases in which the test was repeated, each observer agreed with the former assessment in 66% (PJL) and 62% (RT): this intraobserver error was significant (0-05>p>0-02). On two occasions the negative control was deemed positive, and on seven of 16 (44%) observations the positive control was classed as negative.
Observations with congestive cardiomyopathic heart as substrate were in agreement more often (85% compared with 61%) than with normal heart substrate. Repeat tests were also in agreement more often with cardiomyopathic heart (71% compared with 392 44%) than with normal heart, but the positive control was classed as negative on 50% of the observations with cardiomyopathic heart compared with 38% with normal heart substrate. Table 3 shows the distribution of positive and nega- tive fluorescence results in the different groups. There was no significant difference in the number of sera showing fluorescence on at least one observation (090>p>0.08). Sera from only one normal subject gave a positive result, and all those from the postinfarct/post cardiotomy group showed fluorescence on *at least one occasion. There was no significant difference in the total number and percentage of positive observations within each group (Table 3) . The percentage of positive observations in the miscellaneous control group was 8% and for the post-infarct/postcardiotomy group 50%. When the symptomatic (NYHA) groups 0-IIa with IIb-IV are compared positive fluorescence was seen on at least one occasion in 53% of sera from the milder group and in 59% of those from the more severe group (not significant): and the percentage of positive observations in the milder group was 22% and 23% in the more severe group (not significant).
BIOPSY STUDY Table 4 shows the results of fluorescence on the biopsy specimens. In the hypertrophic group one specimen was of poor quality and unsuitable for interpretation. In the miscellaneous group fibrin and IgG were increased in areas of fibrosis in the cases of constrictive pericarditis, hypertension, and discrete subaortic stenosis. One patient with myocarditis had increased fibrin and IgG, C3, IgM, and IgA fluorescence in the thickened endocardium and IgG and fibrin in the connective tissue. Fibrin and IgG were bound in the septa of the one normal subject. Table 5 shows the serological and biopsy results in patients included in both parts of the study with con-Humoral immunity in cardiomyopathy gestive cardiomyopathy and hypertrophic cardiomyopathy. Six of 13 patients with congestive cardiomyopathy, three of six patients with hypertrophic cardiomyopathy and five of the 12 in the miscellaneous group had some degree of immunofluorescence in the serum. In the first group, absence of positive fluorescence in the serum did not always infer binding of antibody in the biopsy specimen and often fluorescence was seen in both sera and biopsy specimens.
Discussion
The specificity of the immunofluorescence test for anti-heart antibodies in serum was 93% but the sensitivity was only 56%. The test is therefore specific for these antibodies as few false positives occur, and this is borne out in the control group, but the percentage of false negatives is so high that results cannot give a true reflection of the incidence of anti-heart antibodies. Our results show that the antibodies appear to be present to some extent in all forms of heart disease, that they do not differ signifcantly between groups, and that anti-heart antibodies probably reflect nonspecific cardiac damage. This is in agreement with other studies.39 Although sera from all the patients in the post-infarct/post-cardiotomy group showed fluorescence on at least one occasion, only 50% of all the observations in this group were positive, reflecting the low sensitivity of the test. As reported elsewhere'0 the results for the patients with more severe symptoms did not differ significantly either within their groups or between the groups and do not support the previous finding in our laboratory5 or Bolt and Grothey's findings. 2 There were wide interobserver and intraobserver variations: only 73% of observations were in agreement, and on repeat testing the observer agreed with his former assessment on only 66% (PJL) and 62% (RT) of occasions (0-05>p>002). Assessment of fluorescence is subjective and there is no accepted method of quantifying the amount of fluorescence. It is important that tests are performed blind and with more than one observer, otherwise inconsistencies are bound to arise."I 12 In our previous study5 fresh baboon heart was used as substrate; in the present study fresh normal human heart and fresh cardiomyopathic human heart were used and no difference in results was obtained.
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